95233-37-7Relevant articles and documents
A pharmaceutical intermediate 4 - (4 - chlorophenyl) cyclohexyl -1 - formic acid
-
Paragraph 0036; 0037; 0045, (2017/04/19)
The invention belongs to the field of preparation of drug intermediates and particularly relates to a synthesis method of a drug intermediate 4-(4-chlorphenyl) cyclohexyl-1-formic acid. The method comprises the following steps: firstly reacting a compound I with R2SO2Cl in the presence of an acid-binding agent to obtain a compound II; carrying out catalytic coupling reaction on the compound II and a Grignard reagent 4-chlorphenyl magnesium halide under the action of a catalyst to obtain a compound III; and finally hydrolyzing the compound III in alkali liquor to obtain a target product 4-(4-chlorphenyl) cyclohexyl-1-formic acid. According to the synthesis method, all steps in a reaction route are exclusive reactions; and ortho-position and meta-position problems in friedel-crafts reaction are overcome, so that the utilization rate of raw materials is high; the total yield is high; and the cost is low. A main body structure is constructed by a coupling technique, so that the problem that hydrolysate which is formed after a lot of lewis acid used in the friedel-crafts reaction is hydrolyzed needs to be subjected to special treatment is overcome; the method is environment-friendly; and industrialized production is facilitated.
Method for treating animals infected with Babesia spp.
-
, (2008/06/13)
The present invention relates to pharmaceutical compositions for the treatment and/or prophylaxis of protozoal infections caused by Kinetoplastida, Apicomplexa, Anaerobic protozoa and Mircosporidia comprising 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone or a physiologically acceptable salt or other functional derivative thereof as active ingredient and to a method of treating or preventing siad protozoal infections in an animal which comprises administering to said animal an effective amount of siad compound.
Medicaments
-
, (2008/06/13)
A method and certain compositions for treating Pneumocystis carinii infections in a mammal by administering a certain naphthoquinone compound or physiologically acceptable salts thereof.